JP2005526087A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526087A5
JP2005526087A5 JP2003576401A JP2003576401A JP2005526087A5 JP 2005526087 A5 JP2005526087 A5 JP 2005526087A5 JP 2003576401 A JP2003576401 A JP 2003576401A JP 2003576401 A JP2003576401 A JP 2003576401A JP 2005526087 A5 JP2005526087 A5 JP 2005526087A5
Authority
JP
Japan
Prior art keywords
rhinitis
asthma
chronic
allergic
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526087A (ja
Filing date
Publication date
Priority claimed from SE0200844A external-priority patent/SE0200844D0/xx
Application filed filed Critical
Publication of JP2005526087A publication Critical patent/JP2005526087A/ja
Publication of JP2005526087A5 publication Critical patent/JP2005526087A5/ja
Pending legal-status Critical Current

Links

JP2003576401A 2002-03-19 2003-03-17 ケモカインレセプター活性モジュレーターとして有用なピペリジン誘導体 Pending JP2005526087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200844A SE0200844D0 (sv) 2002-03-19 2002-03-19 Chemical compounds
PCT/SE2003/000443 WO2003078395A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
JP2005526087A JP2005526087A (ja) 2005-09-02
JP2005526087A5 true JP2005526087A5 (https=) 2006-04-20

Family

ID=20287326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576401A Pending JP2005526087A (ja) 2002-03-19 2003-03-17 ケモカインレセプター活性モジュレーターとして有用なピペリジン誘導体

Country Status (6)

Country Link
US (2) US7517989B2 (https=)
EP (1) EP1487793A1 (https=)
JP (1) JP2005526087A (https=)
AU (1) AU2003212770A1 (https=)
SE (1) SE0200844D0 (https=)
WO (1) WO2003078395A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6949590B2 (en) * 2002-01-10 2005-09-27 University Of Washington Hydrogels formed by non-covalent linkages
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
US20080200505A1 (en) * 2005-05-27 2008-08-21 Astrazeneca Ab Piperidines for the Treatment of Chemokine Mediated Diseases
WO2007011293A1 (en) * 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8610368B2 (en) 2009-12-21 2013-12-17 Top Victory Investments Ltd. Serial-type light-emitting diode (LED) device
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (https=) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
JPH07501063A (ja) * 1991-11-14 1995-02-02 グラクソ、グループ、リミテッド フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en) 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
EP0912515B1 (en) 1996-07-10 2002-11-13 Schering Corporation 1,4-di-substituted piperidines as muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
IL128524A0 (en) 1996-08-15 2000-01-31 Schering Corp Ether muscarinic antagonists
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
WO1999038514A1 (en) 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
EP1076055B1 (en) 1998-04-28 2004-11-24 Dainippon Pharmaceutical Co., Ltd. 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
AU756484B2 (en) 1998-06-30 2003-01-16 Schering Corporation Muscarinic antagonists
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003529531A (ja) 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
HK1039330B (en) 1999-05-04 2005-12-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
SK1182002A3 (en) 1999-07-28 2002-11-06 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
PL364560A1 (en) 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
EP1633737A1 (en) 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
SE0400925D0 (sv) 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
US20080200505A1 (en) 2005-05-27 2008-08-21 Astrazeneca Ab Piperidines for the Treatment of Chemokine Mediated Diseases
TW200722419A (en) 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives

Similar Documents

Publication Publication Date Title
JP2005526087A5 (https=)
ES2292988T3 (es) Derivados de nicotinamida utiles como inhibidores de pde4.
JP2009532417A5 (https=)
JP5225085B2 (ja) 新規なキャップ化ピラジノイルグアニジンナトリウムチャネル遮断薬
US20110003858A1 (en) Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
RU2008140910A (ru) Новые пиперидины в качестве модуляторов хемокинов (ccr)
JP2008509187A5 (https=)
US20120196854A1 (en) Pharmaceutical composition comprising aromatic heterocyclic compound
NO20024708D0 (no) Behandling av respiratoriske sykdommer
JP2007502829A (ja) 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
TW200307545A (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
JP2014521724A (ja) 一過性受容器電位イオンチャネルｔｒｐａ１の阻害
TW200845998A (en) Heterocyclic compounds useful in treating diseases and conditions
JP2008525397A5 (https=)
JP2017524674A (ja) 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物
HRP20191339T1 (hr) Novi anelirani fenoksiacetamidi
JP2022507118A (ja) 呼吸器疾患の処置のための化合物及び組成物
JP2009532413A5 (https=)
US20060069124A1 (en) Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
TW201006799A (en) Novel compounds active as muscarinic receptor antagonists
CA2667041A1 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
US20030191158A1 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
US20030195233A1 (en) Nicotinamide derivatives useful as PDE4 inhibitors
JP2006504768A (ja) 四級アンモニウム化合物